Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study

Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: D'Aniello, Carmine, Vitale, Maria G., Farnesi, Azzurra, Calvetti, Lorenzo, Laterza, Maria M., Cavaliere, Carla, Della Pepa, Chiara, Conteduca, Vincenza, Crispo, Anna, De Vita, Ferdinando, Grillone, Francesco, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Di Napoli, Marilena, Cecere, Sabrina C., Iovane, Gelsomina, Amore, Alfonso, Piscitelli, Raffaele, Quarto, Giuseppe, Pisconti, Salvatore, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Naglieri, Emanuele, Galli, Luca, Cartenì, Giacomo, De Giorgi, Ugo, Pignata, Sandro, Facchini, Gaetano, Rossetti, Sabrina
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2016
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039205/
https://ncbi.nlm.nih.gov/pubmed/27733829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00331
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars